Inhibition of 3-hydroxy-3-methylglutarylcoenzyme a reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 495-503

  Laezza, Chiara ^a,b   Malfitano, Anna Maria ^c   Proto, Maria Chiara ^c   Esposito, Iolanda ^b   Gazzerro, Patrizia ^c   Formisano, Pietro ^b   Pisanti, Simona ^c   Santoro, Antonietta ^c   Caruso, Maria Gabriella ^d   Bifulco, Maurizio ^c  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d Natl Institute of Digestive Disease   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 2' F ANANDAMIDE; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANANDAMIDE; CANNABINOID 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN PRENYLATION;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYUNSATURATED ALKAMIDES; RAS PROTEINS;

EID: 77953561661     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0009     Document Type: Article

References (28)

1. Bifulco M & Di Marzo V 2002 Targeting the endocannabinoid system in cancer therapy: a call for further research. Nature Medicine 6 547-550.
2. Bifulco M, Perillo B, Saji M, Laezza C, Tedesco I, Kohn LD & Aloj SM 1995 Regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. I. Identification and characterization of a cyclic AMP-responsive element in the rat reductase promoter. Journal of Biological Chemistry 270 15231-15236.
3. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L & Di Marzo V 2001 Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB Journal 15 2745-2747.
4. Bifulco M, Laezza C, Pisanti S & Gazzerro P 2006 Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 148 123-135.
5. Bifulco M, Malfitano AM, Pisanti S & Laezza C 2008 Endocannabinoids in endocrine and related tumours. Endocrine-Related Cancer 15 391-408.
6. Bosier B, Hermans E & Lambert D 2008 Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. British Journal of Pharmacology 155 24-33.
7. Bosier B, Hermans E & Lambert DM 2009 Concomitant activation of adenylyl cyclase suppresses the opposite influences of CB(1) cannabinoid receptor agonists on tyrosine hydroxylase expression. Biochemical Pharmacology 15 216-227.
8. Brown MS, Goldstein JL & Dietschy JM 1979 Active and inactive forms of 3-hydroxy-3-methylglutaryl CoA reductase. Journal of Biological Chemistry 254 5144-5149.
9. Demuth DG & Molleman A 2006 Cannabinoid signalling. Life Sciences 78 549-563.
10. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M & Di Marzo V 1998 The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. PNAS 95 8375-8380.
11. Goldstein JL & Brown MS 1990 Regulation of the mevalonate pathway. Nature 343 425-430.
12. Graaf MR, Richel DJ, van Noorden CJF & Guchelaar HJ 2004 Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treatment Reviews 30 609-641.
13. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G et al. 2006 Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 312 363-373.
14. Herring AC, Koh WS & Kaminski NE 1998 Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kB elements by cannabinol, a minimally CNS-active cannabinoid. Biochemical Pharmacology 55 1013-1023.
15. Howlett AC & Fleming RM 1984 Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology 26 532-538.
16. Konstantinopoulos PA, Karamouzis MV & Papavassiliou AG 2007 Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews. Drug Discovery 6 541-555.
17. Laezza C, Di Marzo V & Bifulco M 1998 v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. PNAS 95 13646-13651.
18. Laezza C, Notarnicola M, Caruso MG, Messa C, Macchia M, Bertini S, Minutolo F, Portella G, Fiorentino L, Stingo S et al. 2006a N6- isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB Journal 20 412-418.
19. Laezza C, Pisanti S, Crescenzi E & Bifulco M 2006b Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Letters 580 6076-6082.
20. Laezza C, Pisanti S, Malfitano AM & Bifulco M 2008 The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocrine-Related Cancer 15 965-974.
21. McTaggart SJ 2006 Isoprenylated proteins. Cellular and Molecular Life Sciences 63 255-267.
22. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M & Di Marzo V 1999 Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters 463 235-240.
23. Mondola P, Serù R, Santillo M, Damiano S, Bifulco M, Laezza C, Formisano P, Rotilio G & Ciriolo MR 2002 Effect of Cu,Zn superoxide dismutase on cholesterol metabolism in human epatocarcinoma (HepG2) cells. Biochemical and Biophysical Research Communications 295 603-609.
24. Nakanish M, Goldstein JL & Brown MS 1988 Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Journal of Biological Chemistry 263 8929-8937.
25. Ngo TT, Bennett MK, Bourgeois AL, Toth JI & Osborne TF 2002 A role for cyclicAMPresponse element-binding protein (CREB) but not the highly similar ATF-2 protein in sterol regulation of the promoter for 3-hydroxy-3- methylglutaryl coenzyme A reductase. Journal of Biological Chemistry 277 33901-33905.
26. Perillo B, Tedesco I, Laezza C, Santillo M, Romano A, Aloj SM & Bifulco M 1995 Regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. II. Down-regulation by v-K-ras oncogene. Journal of Biological Chemistry 270 15237-15241.
27. Porcella A, Gessa GL & Pani L 1998 Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos related antigens in the rat brain. European Journal of Neuroscience 10 1743-1751. (Pubitemid 128707225)
28. Sands WA & Palmer TM 2008 Regulating gene transcription in response to cyclic AMP elevation. Cellular Signalling 20 460-466.